The size of the nuclear medicine diagnostic market in Europe is estimated at $3.03 billion in 2018 and is expected to reach $5.24 billion by 2023, at a compound annual growth rate (CAGR) of 11.60%.
Nuclear medicine is a branch of medicine that uses radiation to deliver information about the functioning of a person's specific organs or to treat a disease. In most cases, the information will assist the physicians to make a quick, accurate diagnosis of the patient's illness.
Drivers and Restraints
Till today, SPECT imaging was the most conventional modality for nuclear medicine applications such as nuclear cardiology procedures. However, the trend is soon going to see a downturn owing to a shortage of molybdenum-99 isotope which is, in turn, will lead to a deficiency of Technetium-99, which is the by-product of molybdenum. Therefore, PET imaging products which include hybrid PET-CT scanners is expected to account for potentially hefty market size in the near future.
The emerging-market will be a fusion of nuclear imaging with different diagnostic imaging products such as SPECT/CT, PET/CT, and MRI/PET. This provides a full range of imaging scans through the same unit and at the same time. PET market is expected to witness faster growth compared to SPECT imaging as it delivers higher resolution images. Lack of availability of technetium-99m is also forcing the industry to look for alternative diagnostic procedures
Increasing usage of SPECT and PET in medical diagnostics, rising awareness among people about radiopharmaceuticals, and ready availability of radiopharmaceuticals are some of the major factors driving the growth of the market. However, shorter half-life of radioisotopes, regulatory guidelines, high capital investment, and reimbursement issues are the key factors restraining market growth.
This research report segmented and sub-segmented into the following categories:
Furthermore, on the basis of geography, the European Market is analyzed under various regions namely, UK, Spain, Italy, Germany, and France.
Most promising companies operating in the European Nuclear Medicine Diagnostics Market are Cardinal Health, Inc., Bracco Imaging S.p.A, GE Healthcare, Eczacibasi-Monrol Nuclear Products, Nordion, Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc., Advanced Accelerator Applications S.A., IBA Molecular Imaging & Mallinckrodt plc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Type
5.1.1 SPECT
5.1.1.1 Technetium-99m
5.1.1.2 Thallium-201
5.1.1.3 Gallium-67
5.1.1.4 Iodine-23
5.1.1.5 Others
5.1.2 PET
5.1.2.1 Fluorine-18
5.1.2.2 Rubidium-82
5.1.2.3 Others
5.2 By Application
5.2.1 Cardiology
5.2.2 Lymphoma
5.2.3 Thyroid
5.2.4 Neurology
5.2.5 Oncology
5.2.6 Others
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Cardinal Health Inc.
8.3 Bracco Imaging S.p.A
8.4 Eczacibasi-Monrol Nuclear Products
8.5 Nordion, Inc.
8.6 Bayer Healthcare
8.7 Lantheus Medical Imaging, Inc.
8.8 Advanced Accelerator Applications S.A.
8.9 IBA Molecular Imaging
8.10 Mallinckrodt plc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
